XML 90 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Contracts - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 16, 2021
USD ($)
Dec. 13, 2019
USD ($)
Product
Oct. 26, 2015
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2019
License
Dec. 31, 2019
USD ($)
Dec. 31, 2021
USD ($)
Option
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jul. 01, 2021
Apr. 30, 2021
Apr. 30, 2020
USD ($)
Dec. 12, 2019
Mar. 31, 2016
Feb. 12, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Non-current deferred revenue       $ 12,323,000     $ 12,323,000 $ 11,776,000              
Current deferred revenue       $ 1,011,000     1,011,000 2,341,000              
Research and development expense [1]             $ 438,633,000 266,946,000 $ 179,362,000            
Date of joint venture agreement             Dec. 19, 2015                
Operating expenses             $ 541,435,000 355,154,000 242,850,000            
Stock-based compensation expense             102,390,000 66,018,000 49,524,000            
Net loss of joint venture             377,661,000 (348,865,000) 66,858,000            
Issuance of common shares, value             222,175,000 973,381,000 414,789,000            
Proceeds from Issuance of Common Stock             213,267,000 982,289,000 415,019,000            
Other (expense) income             $ 6,003,000 6,379,000 26,033,000            
Casebia Therapeutics Limited Liability Partnership [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Date of formation of joint venture entity             Feb. 12, 2016                
Equity method investment, ownership percentage       50.00%     50.00%           50.00% 50.00% 50.00%
Percentage of partnership interests   100.00%                          
Partnership outstanding maximum exchange amount   $ 22,000,000.0                          
Operating expenses   $ 6,000,000.0                          
Number of products | Product   2                          
Percentage of research and development costs   50.00%                          
Percentage sharing of profit (loss) from sale of product   50.00%                          
Non-refundable one-time option payment   $ 20,000,000.0                          
Equity method investment       $ 0     $ 0                
Stock-based compensation expense                 5,500,000            
Unrecognized equity method losses in excess of Company's interest                 72,000,000.0            
Business combination, consideration transferred             41,000,000.0                
Net assets acquired       16,000,000.0     16,000,000.0                
Fair value of assets and liabilities       16,000,000.0     16,000,000.0                
Payment to acquire business             $ 16,000,000.0                
Number of options exercised under agreement | Option             2                
Casebia Therapeutics Limited Liability Partnership [Member] | Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Net loss of joint venture   $ 58,800,000                          
Research and Development [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Stock-based compensation expense             $ 59,683,000 35,120,000 23,273,000            
Research and Development Services [Member] | Casebia Therapeutics Limited Liability Partnership [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Fair value of obligations       20,200,000     20,200,000                
Future Delivery of up to Two Options [Member] | Casebia Therapeutics Limited Liability Partnership [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Fair value of obligations       4,800,000     4,800,000                
A&R Vertex JDCA [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Percentage of net profits and net losses                   40.00% 40.00%        
2019 Option Agreement [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Research and development expense             7,000,000.0 13,200,000              
2019 Option Agreement [Member] | Casebia Therapeutics Limited Liability Partnership [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Business combination, consideration transferred             25,000,000.0                
Fair value of controlling interest obtained             32,000,000.0                
Payment to acquire business             16,000,000.0                
2019 Option Agreement [Member] | Research and Development [Member] | Casebia Therapeutics Limited Liability Partnership [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Business combination, consideration transferred             20,200,000                
2019 Option Agreement [Member] | Certain Options [Member] | Casebia Therapeutics Limited Liability Partnership [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Business combination, consideration transferred             4,800,000                
2019 Casebia Agreement [Member] | Other Current Liabilities [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Research obligation               7,000,000.0              
2019 Casebia Agreement [Member] | Other Long-term Liabilities [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Research obligation       4,800,000     4,800,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Nonrefundable upfront payment received     $ 75,000,000.0       $ 175,000,000.0                
Percentage of exchange payment of research and development costs             50.00%                
Number of options would not be exercised under agreement | Option             1                
Number of remaining options under agreement | Option             4                
Transaction price             $ 268,600,000                
Non-current deferred revenue       12,300,000     12,300,000 11,800,000              
Non-cash consideration received             10,000,000.0                
Transaction price allocated to remaining performance obligations       12,300,000     12,300,000                
Revenue             913,100,000   289,100,000            
Current deferred revenue       0.0     0.0 400,000              
Collaboration revenue                 30,000,000.0            
Maximum potential future payments             775,000,000.0                
Research and development expense             111,600,000 48,600,000 29,200,000            
Reimbursements from research and license agreements             47,400,000 $ 28,200,000 15,900,000            
Collaborative arrangement, license rights reacquired by waiving payment owed             10,000,000.0                
Non-cash consideration expensed upon execution of collaborative agreement             10,000,000.0                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Research and Development [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Variable consideration received             25,000,000.0                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Milestone payment receivable       420,000,000.0     420,000,000.0                
Milestone payment receivable       410,000,000.0     410,000,000.0                
Transaction price allocated to remaining performance obligations       46,700,000     46,700,000                
Revenue                 76,700,000            
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | DM1 R&D Services [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             1,700,000                
Transaction price allocated to remaining performance obligations       1,100,000     1,100,000                
Revenue                 100,000            
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | DM1 R&D Services [Member] | Research and Development [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Variable consideration received             800,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | DMD License [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             224,600,000                
Transaction price allocated to remaining performance obligations       151,100,000     151,100,000                
Revenue                 289,100,000            
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | DM1 License [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             76,200,000                
Transaction price allocated to remaining performance obligations       51,300,000     51,300,000                
Revenue             12,000,000.0   202,400,000            
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Specified Target Option Material Right [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             17,500,000                
Transaction price allocated to remaining performance obligations       11,800,000     11,800,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options Material Rights One [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             25,000,000.0                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options Material Rights Two [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             22,200,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaboration Target Options Material Rights Three [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             22,200,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Collaborative Arrangement Material Rights Fourth Exclusive License [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             10,000,000.0                
Transaction price allocated to remaining performance obligations       6,700,000     6,700,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Exclusive License [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Revenue             900,000,000.0                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Waiving of Vertex Material Right [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Revenue                 6,700,000            
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Research and Development Services [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Revenue                 $ 100,000            
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2015 Collaboration Agreement [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Milestone payment receivable       395,000,000.0     $ 395,000,000.0                
Percentage of exchange payment of research and development costs             50.00%                
Number of options would not be exercised under agreement | Option             1                
Number of remaining options under agreement | Option             4                
Non-current deferred revenue       57,800,000     $ 57,800,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | 2019 Collaboration Agreement [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Nonrefundable upfront payment received             175,000,000.0                
Variable consideration adjusted to transaction price       12,500,000                      
Revenue recognized       12,000,000.0                      
Maximum potential payments       825,000,000     $ 825,000,000                
Percentage of exchange payment of research and development costs             50.00%                
Transaction price allocated to remaining performance obligations       500,000     $ 500,000                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Joint Development Agreement [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Up-front payment received             $ 7,000,000.0                
Agreement description             In connection with the JDA, the Company received a $7.0 million up-front payment from Vertex and subsequently received a one-time low seven-digit milestone payment upon the dosing of the second patient in a clinical trial with the initial product candidate.                
Vertex Pharmaceuticals Incorporated and Certain of its Subsidiaries [Member] | Exercise of Exclusive Option [Member] | Collaboration Target Options [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Milestone payment receivable       10,000,000     $ 10,000,000                
Vertex Pharmaceuticals Inc [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Maximum potential future payments             200,000,000.0                
Vertex Pharmaceuticals Inc [Member] | Exclusive License [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Estimated standalone selling price for single collaboration             900,000,000.0                
Vertex Pharmaceuticals Inc [Member] | A&R Vertex JDCA [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Up-front payment received $ 900,000,000.0           $ 900,000,000.0                
Milestone payment receivable $ 200,000,000.0                            
Percentage of net profits and net losses                   60.00% 60.00%        
Additional interest of percentage             10.00%                
Vertex Pharmaceuticals Inc [Member] | 2015 Collaboration Agreement [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Aggregate amount in option exercise payments received           $ 30,000,000.0                  
Number of exclusive license targets | License         3                    
Vertex Pharmaceuticals Inc [Member] | 2019 Collaboration Agreement [Member]                              
Research and Development Arrangement, Contract to Perform for Others [Line Items]                              
Milestone payment receivable       12,500,000     $ 12,500,000         $ 25,000,000.0      
Remaining milestone payment receivable       $ 775,000,000.0     $ 775,000,000.0                
[1] Including the following amounts of research and development from a related party, see Note 9